Trump Launches New Women’s Health Division and White House Task Force to Improve Medical Research

Image Credit: AP

US President Donald Trump has signed an executive order establishing a new Women’s Health Division within the National Institutes of Health (NIH) and a White House task force aimed at improving medical research and healthcare for women. Announced on October 19, 2026, the initiative is being championed by First Lady Melania Trump and is intended to address longstanding gaps in the understanding, diagnosis and treatment of conditions affecting women throughout their lives.

The new division is expected to be established within 90 days and will work alongside the NIH’s existing Office of Research on Women’s Health, which was established in 1990. Unlike the existing office, the new division will have a broader mandate, focusing not only on research but also on translating scientific discoveries into practical treatments, improving diagnosis and expanding access to healthcare.

According to Reuters, the White House task force will be co-led by White House Chief of Staff Susie Wiles and Health and Human Services Secretary Robert F. Kennedy Jr. It will coordinate efforts across government agencies to improve prevention, diagnosis and treatment while encouraging greater inclusion of women and girls in clinical trials.

The initiative will focus on a wide range of conditions, including cardiovascular disease, cancer, autoimmune disorders, chronic pain, endometriosis, uterine fibroids, infertility, menopause, Alzheimer’s disease and osteoporosis. These areas have attracted increasing attention from researchers and healthcare professionals because important questions about how diseases develop, present and respond to treatment in women remain unanswered.

Melania Trump said the initiative would help accelerate medical discoveries and make breakthroughs more accessible and affordable. She also highlighted the potential of artificial intelligence and advanced medical technologies to speed up research and improve treatment options. President Trump credited the first lady with bringing the idea to his attention and helping develop the proposal.

However, the announcement has also raised questions about funding and implementation. The executive order does not specify a dedicated funding amount for the new division or set out a detailed financial commitment for accelerating research. The administration has also faced criticism over reductions in federal health research spending and staffing, prompting concerns about how effectively the new initiative can deliver its objectives.

Another significant aspect of the order is its decision to revoke a women’s health research initiative established under former President Joe Biden in 2024. That earlier programme sought to strengthen research into conditions affecting women and had attracted substantial federal investment. While the Trump administration argues that its new approach will improve coordination and bring research findings into clinical practice more efficiently, critics have questioned whether creating another division will produce meaningful progress without clear funding commitments.

The announcement comes amid wider debate in the United States over reproductive healthcare, hormone therapy and the future direction of public health policy. Although the new initiative promises greater attention to women’s medical needs, its effectiveness will ultimately depend on sustained research investment, scientific independence and the ability to turn discoveries into accessible treatments.

With the new division expected to take shape within the next three months, attention will now turn to its structure, funding and research priorities. The initiative presents an opportunity to address persistent gaps in women’s healthcare, but its long-term impact will depend on whether the administration can translate its promises into measurable improvements in diagnosis, treatment and health outcomes for women and girls across the United States.